210 related articles for article (PubMed ID: 33249047)
1. CAR T-cells profiling in carcinogenesis and tumorigenesis: An overview of CAR T-cells cancer therapy.
Samadani AA; Keymoradzdeh A; Shams S; Soleymanpour A; Rashidy-Pour A; Hashemian H; Vahidi S; Norollahi SE
Int Immunopharmacol; 2021 Jan; 90():107201. PubMed ID: 33249047
[TBL] [Abstract][Full Text] [Related]
2. Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy.
Zhu L; Yang X; Zhong D; Xie S; Shi W; Li Y; Hou X; HuaYao ; Zhou H; Zhao M; Ding Z; Zhao X; Mo F; Yin S; Liu A; Lu X
J Immunol Res; 2020; 2020():2454907. PubMed ID: 32964055
[TBL] [Abstract][Full Text] [Related]
3. CAR T cells for solid tumors - developments to watch in 2023.
Trefny MP; Kobold S
Expert Opin Biol Ther; 2024 Apr; 24(4):207-211. PubMed ID: 38526025
[No Abstract] [Full Text] [Related]
4. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy.
Sheih A; Voillet V; Hanafi LA; DeBerg HA; Yajima M; Hawkins R; Gersuk V; Riddell SR; Maloney DG; Wohlfahrt ME; Pande D; Enstrom MR; Kiem HP; Adair JE; Gottardo R; Linsley PS; Turtle CJ
Nat Commun; 2020 Jan; 11(1):219. PubMed ID: 31924795
[TBL] [Abstract][Full Text] [Related]
5. Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy.
Gabelli M; Oporto-Espuelas M; Burridge S; Chu J; Farish S; Hedges E; Ware K; Williams L; Young L; Alajangi R; Ancliff P; Bartram J; Bonney D; Chenchara L; Chiesa R; Cugno C; Hodby K; Jalowiec KA; Lazareva A; Lucchini G; Mirci-Danicar OC; Mullanfiroze K; Pavasovic V; Rao A; Rao K; Riley L; Samarasinghe S; Shenton G; Silva J; Vora A; Hough R; Amrolia PJ; Ghorashian S
Blood Adv; 2024 Apr; 8(8):1959-1963. PubMed ID: 37820111
[No Abstract] [Full Text] [Related]
6. Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.
Pinte L; Cunningham A; Trébéden-Negre H; Nikiforow S; Ritz J
Front Immunol; 2020; 11():608485. PubMed ID: 33658994
[TBL] [Abstract][Full Text] [Related]
7. CAR T-Cell Production Using Nonviral Approaches.
Lukjanov V; Koutná I; Šimara P
J Immunol Res; 2021; 2021():6644685. PubMed ID: 33855089
[TBL] [Abstract][Full Text] [Related]
8. Cas13d-mediated gene knockdown in CAR T cells: towards off-the-shelf cancer treatment.
Johnston M; Urban N; Dincer C
Signal Transduct Target Ther; 2024 Apr; 9(1):113. PubMed ID: 38670950
[No Abstract] [Full Text] [Related]
9. Overcoming the challenges encountered in CAR-T therapy: latest updates from the 2023 ASH annual conference.
Zhang T; Zhang Y; Wei J
Front Immunol; 2024; 15():1389324. PubMed ID: 38660304
[TBL] [Abstract][Full Text] [Related]
10. Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T-cells (CAR-T): A comprehensive review on incidence, risk factors and current management.
Galli E; Fresa A; Bellesi S; Metafuni E; Maiolo E; Pansini I; Frioni F; Autore F; Limongiello MA; Innocenti I; Giammarco S; Chiusolo P; Zini G; Sorà F
Eur J Haematol; 2024 Feb; 112(2):184-196. PubMed ID: 37491951
[TBL] [Abstract][Full Text] [Related]
11. Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy.
Bangayan NJ; Wang L; Burton Sojo G; Noguchi M; Cheng D; Ta L; Gunn D; Mao Z; Liu S; Yin Q; Riedinger M; Li K; Wu AM; Stoyanova T; Witte ON
Proc Natl Acad Sci U S A; 2023 Nov; 120(47):e2312374120. PubMed ID: 37963244
[TBL] [Abstract][Full Text] [Related]
12. [Cellular immunotherapies for malignancies - How do they work and what are the side effects?].
Läubli H
Ther Umsch; 2023 Oct; 80(8):348-352. PubMed ID: 37971524
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of CAR-T treatment toward the potential risk of second malignancies.
Martino M; Porto G; Policastro G; Alati C; Loteta B; Micó MC; Argiró C; Altomonte M; Moscato T; Labate D; Dattola V; Rao CM; Cogliandro F; Canale FA; Naso V; Filippelli G; Iaria A; Pitea M
Front Immunol; 2024; 15():1384002. PubMed ID: 38756776
[No Abstract] [Full Text] [Related]
14. Genetic re-direction of canine primary T cells for clinical trial use in pet dogs with spontaneous cancer.
Rotolo A; Atherton MJ; Kasper BT; Haran KP; Mason NJ
STAR Protoc; 2021 Dec; 2(4):100905. PubMed ID: 34746864
[TBL] [Abstract][Full Text] [Related]
15. FOXO1 enhances CAR T cell fitness and function.
Marchal I
Nat Biotechnol; 2024 May; 42(5):699. PubMed ID: 38760553
[No Abstract] [Full Text] [Related]
16. T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology.
Sharpe ME
Toxicol Pathol; 2018 Feb; 46(2):131-146. PubMed ID: 29471776
[TBL] [Abstract][Full Text] [Related]
17. Analysis of pre-treatment tumors reveals gatekeepers of response to CAR T cells.
Singh N
Mol Ther; 2024 Mar; 32(3):567-568. PubMed ID: 38402613
[No Abstract] [Full Text] [Related]
18. Do cutting-edge CAR-T-cell therapies cause cancer? What the data say.
Willyard C
Nature; 2024 May; 629(8010):22-24. PubMed ID: 38689052
[No Abstract] [Full Text] [Related]
19. An update on ICU outcomes in patients after CAR T therapy: A four-year tertiary UK centre experience.
Scourfield L; Pirani T; Singh N; Saha R; Kuhnl A; Sanderson R; Metaxa V
J Crit Care; 2024 Apr; 80():154511. PubMed ID: 38157684
[No Abstract] [Full Text] [Related]
20. CAR-T overdrive: harnessing inosine for metabolic rewiring and stemness induction.
Farrera-Sal M; Schmueck-Henneresse M
Signal Transduct Target Ther; 2024 May; 9(1):120. PubMed ID: 38714686
[No Abstract] [Full Text] [Related]
[Next] [New Search]
